Ascendis Pharma A/S annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ascendis Pharma A/S Revenue Growth & History (ASND)
Ascendis Pharma A/S reported €720.1M in revenue for fiscal 2025, an increase of 98.03% from the previous fiscal year.
View full Ascendis Pharma A/S company overviewAscendis Pharma A/S annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €720.1M | €356.5M | +98.03% |
| 2024 | 2024-12-31 | €363.6M | €96.9M | +36.34% |
| 2023 | 2023-12-31 | €266.7M | €215.5M | +421.20% |
| 2022 | 2022-12-31 | €51.2M | €43.4M | +557.93% |
| 2021 | 2021-12-31 | €7.8M | €825,000 | +11.87% |
| 2020 | 2020-12-31 | €7.0M | −€6.4M | −48.01% |
| 2019 | 2019-12-31 | €13.4M | €2.8M | +26.41% |
| 2018 | 2018-12-31 | €10.6M | €9.1M | +591.57% |
| 2017 | 2017-12-31 | €1.5M | −€3.1M | −66.78% |
| 2016 | 2016-12-31 | €4.6M | −€3.5M | −43.26% |
| 2015 | 2015-12-31 | €8.1M | — | — |
Ascendis Pharma A/S quarterly revenue
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €339.3M | €181.2M | +114.68% |
| Q1 2026 | 2026-03-31 | €246.6M | €145.6M | +144.27% |
| Q4 2025 | 2025-12-31 | €247.5M | €73.6M | +42.31% |
| Q3 2025 | 2025-09-30 | €213.6M | €155.8M | +269.40% |
| Q2 2025 | 2025-06-30 | €158.0M | €122.0M | +339.04% |
| Q1 2025 | 2025-03-31 | €101.0M | €5.1M | +5.28% |
| Q4 2024 | 2024-12-31 | €173.9M | €36.2M | +26.30% |
| Q3 2024 | 2024-09-30 | €57.8M | €9.8M | +20.40% |
| Q2 2024 | 2024-06-30 | €36.0M | −€11.4M | −24.04% |
| Q1 2024 | 2024-03-31 | €95.9M | €62.3M | +185.49% |
| Q4 2023 | 2023-12-31 | €137.7M | €114.8M | +501.42% |
| Q3 2023 | 2023-09-30 | €48.0M | €32.7M | +214.15% |
| Q2 2023 | 2023-06-30 | €47.4M | €41.2M | +669.37% |
| Q1 2023 | 2023-03-31 | €33.6M | €26.8M | +391.93% |
| Q4 2022 | 2022-12-31 | €22.9M | €18.0M | +367.55% |
| Q3 2022 | 2022-09-30 | €15.3M | €14.2M | +1273.76% |
| Q2 2022 | 2022-06-30 | €6.2M | €5.1M | +502.74% |
| Q1 2022 | 2022-03-31 | €6.8M | €6.1M | +815.28% |
| Q4 2021 | 2021-12-31 | €4.9M | €4.4M | +815.33% |
| Q3 2021 | 2021-09-30 | €1.1M | −€1.6M | −59.63% |
| Q2 2021 | 2021-06-30 | €1.0M | −€414,000 | −28.83% |
| Q1 2021 | 2021-03-31 | €746,000 | −€1.5M | −66.47% |
| Q4 2020 | 2020-12-31 | €535,000 | −€2.0M | −78.66% |
| Q3 2020 | 2020-09-30 | €2.8M | €514,000 | +22.92% |
| Q2 2020 | 2020-06-30 | €1.4M | −€1.8M | −55.28% |
| Q1 2020 | 2020-03-31 | €2.2M | −€3.2M | −58.90% |
| Q4 2019 | 2019-12-31 | €2.5M | −€8.0M | −76.16% |
| Q3 2019 | 2019-09-30 | €2.2M | €2.2M | +11115.00% |
| Q2 2019 | 2019-06-30 | €3.2M | €3.2M | +17738.89% |
| Q1 2019 | 2019-03-31 | €5.4M | €5.4M | +19235.71% |
| Q4 2018 | 2018-12-31 | €10.5M | €10.2M | +3655.36% |
| Q3 2018 | 2018-09-30 | €20,000 | −€414,000 | −95.39% |
| Q2 2018 | 2018-06-30 | €18,000 | −€426,000 | −95.95% |
| Q1 2018 | 2018-03-31 | €28,000 | −€344,000 | −92.47% |
| Q4 2017 | 2017-12-31 | €280,000 | — | — |
| Q3 2017 | 2017-09-30 | €434,000 | — | — |
| Q2 2017 | 2017-06-30 | €444,000 | — | — |
| Q1 2017 | 2017-03-31 | €372,000 | — | — |
Ascendis Pharma A/S revenue growth trends
Over the last five reported fiscal years, revenue grew from €7.0M to €720.1M, a compound annual growth rate of 152.96%. Ascendis Pharma A/S's latest reported quarter, Q2 2026, generated €339.3M in revenue, an increase of 114.68% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Ascendis Pharma A/S source filings ↗